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PreviewsE2F1 can paradoxically function as both 
tumor suppressor and oncogene (Trimar-
chi and Lees, 2002). Induction of E2F1 
could serve in the capacity of oncogene 
surveillance, whereby cells that have 
sustained a mutation in the RB pathway, 
known to be defective in many human 
cancers, could be eliminated. To this end, 
several components of the core apop-
tosis-inducing machinery (caspases, 
Apaf1) have been identified as E2F1 tar-
gets (Nahle et al., 2002). It is thought that 
cancer could arise through deregulation 
of oncogene-induced apoptosis.
The E2F family of tran-
scription factors are known 
regulators of mammalian 
proliferation, held in check 
by the retinoblastoma tumor 
suppressor (pRB) family 
(Trimarchi and Lees, 2002; 
Blais and Dynlacht, 2004). 
The family can be subdivided 
into activators (E2F1-3) and 
repressors (E2F4-8). Mito-
genic signaling promotes 
cyclin-dependent kinase 
(CDK)-mediated pRB phos-
phorylation, which releases 
an unrestrained, active tran-
scription factor. Release 
of active E2F1 is a double-
edged sword for cell survival: 
on the one hand, E2F1 can 
activate genes required for 
proliferation, but on the other, 
it could potentially activate 
apoptosis-related genes as 
well. E2F1 appears to be the 
strongest inducer of apopto-
sis among the activator E2Fs, 
and this specificity appears 
to stem from a protein domain (“marked 
box”) restricted to this family member 
(Hallstrom and Nevins, 2003). Although 
at least one protein has been found to 
specifically interact with this domain 
(Hallstrom and Nevins, 2006), how 
the apoptotic decision is regulated at 
the cellular level and how the balance 
between disparate E2F1 functions—pro-
liferation and apoptosis—is achieved are 
not completely understood.
Thus, one may ask the question: What 
is the molecular circuitry that tips the 
balance in favor of proliferation in some 
settings at the expense of apoptosis, and 
how does E2F mediate this process? 
Earlier work from the Nevins laboratory 
had indicated that growth factor-induced 
PI3 kinase (PI3K) and Akt pathways, but 
not activation of the mitogen-activated 
protein kinase kinase (MEK), could influ-
ence the outcome, promoting prolif-
eration rather than apoptosis (Hallstrom 
and Nevins, 2003, 2006). Recent work 
from the Nevins laboratory now sheds 
considerable light on this subject (Hall-
strom et al., 2008). Using genome-wide 
profiling of rat fibroblasts (REF52), Hall-
strom and colleagues identi-
fied genes that are activated 
upon enforced expression 
of E2F1 yet repressed in a 
PI3K-dependent manner 
in the presence of serum 
growth factors. Interestingly, 
the subset of genes unaf-
fected by serum represent 
canonical E2F target genes 
involved in cell-cycle pro-
gression and DNA replication 
(Ren et al., 2002), while the 
genes specifically repressed 
by serum appear to reflect a 
multitude of heterogeneous 
pathways without an obvious 
or intrinsic cell-cycle associa-
tion. Although these studies 
were performed using a PI3K 
inhibitor, LY294002, comple-
mentary experiments in which 
PI3K was overexpressed con-
firm the observation.
Reasoning that these 
serum-repressed targets could 
influence the decision to com-
mit suicide, eleven candidate 
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Figure 1. The Fateful Intersection of E2F1 and PI3K Pathways in 
Normal and Cancer Cells
Growth factors stimulate proliferation through two branches involving dis-
tinct CDK- and PI3K-Akt kinase pathways that simultaneously liberate E2F1 
activity while suppressing apoptosis. Normal growth is characterized by an 
E2F1-mediated balancing act that promotes expression of cell-cycle genes 
and apoptosis to eliminate cells with deregulated E2F-1 activity. Hyperactivity 
or mutations in the PI3K pathway could abnormally suppress the apoptotic 
arm, promoting inappropriate proliferation and tumorigenesis.Cancer Cell 13, January 2008 ©2008 Elsevier Inc. 
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Previewsgenes were knocked down, and apopto-
sis was examined. The most impressive 
relief of E2F-mediated apoptosis was 
obtained by suppressing expression of 
AMP-activated protein kinase, AMPKα2, 
a central regulator of energy homeosta-
sis in the face of nutrient and ATP deple-
tion. Depletion of AMPKα2 renders both 
normal human fibroblasts and tumor 
cells resistant to E2F-mediated apop-
tosis. Conversely, ectopic expression of 
AMPKα2 synergistically enhances apop-
tosis in an E2F1-dependent manner. 
Given that E2F1 induces apoptosis in 
cells rendered quiescent through mito-
gen deprivation, it is likely that AMPKα2 
is one critical sensor of this nutrient-poor 
state that pushes cells in the direction 
of death (Figure 1). If this hypothesis 
is correct, several mechanistic predic-
tions can be made regarding a direct 
role for AMPKα2 activity in apoptosis. 
One prediction would be that induc-
ers of AMPKα2 activity should actu-
ate E2F1-mediated apoptosis. Indeed, 
as predicted, treatment of cells with an 
AMP analog, AICAR, which activates 
AMPK, induces apoptosis in an E2F1- 
and AMPKα2-dependent manner.
The importance of these findings 
would be greatly enhanced if they trans-
lated from a tissue culture model to the 
clinic. Moreover, given the well-estab-
lished role of pRB and PI3K pathways 
in human cancer, prognostic and thera-
peutic possibilities might also be envi-
sioned. To test this notion, Hallstrom 
and colleagues compared their genome-
wide expression profiles (obtained from 
rat fibroblasts) with a compendium of 
microarray data obtained from several 
independent human breast and ovarian 
cancer data sets. The authors examined 
genes induced by E2F1 that fell into two 
categories: those that were not inhibited 
by PI3K and a second group that was 
repressed in response to serum-induced 
PI3K activation. Interestingly, using hier-
archical clustering of microarray data, 
expression profiles could be used to 
reveal two groups of breast tumors with 
distinct signatures: one group displayed 2 Cancer Cell 13, January 2008 ©2008 Elsevlow levels of expression of the PI3K-
repressed, proapoptotic class of genes 
at the expense of the PI3K-neutral ones, 
while the other group of tumors exhibited 
the inverse pattern. A cohort of ovarian 
tumors could be similarly segregated, 
allowing the authors to distinguish “high 
apoptotic” and “low apoptotic” cancer 
patients. When these tumor samples 
were analyzed using Kaplan-Meier sur-
vival curves, a remarkable trend was 
apparent: those patients with the lowest-
level expression of PI3K-repressed genes 
exhibited a worse prognosis, including a 
shorter survival period and higher rate 
of recurrence. Advanced stage tumors 
had a greater association with reduced 
expression of these genes than did ear-
lier stage tumors. Thus, it would appear 
that a PI3K activation signature could 
well determine the prognosis of at least 
a subset of human cancers.
This study further illustrates the use 
of metagene analyses in the delineation 
of critical pathways activated in tumors 
and provides fertile ground for addi-
tional prognostic and therapeutic pre-
dictions (Bild et al., 2006). Clearly, E2F1 
occupies a nodal point that critically 
influences whether a cell proliferates or 
dies. Exactly how does PI3K modulate 
the activity of E2F1? It will be important 
to uncover the complete compendium 
of genes that convey the death signal 
emanating from E2F1, since AMPKα2 
and two other genes revealed in this 
study (Cyp26b1 or Nr4a3, a regulator of 
retinoic acid metabolism and a nuclear 
receptor family member, respectively) 
are likely to represent the proverbial tip 
of the iceberg. Since secondary waves 
of expression occur upon enforced 
expression of E2F1 and drug treatment, 
it will be important to establish which of 
the noncanonical, presumptive E2F1 tar-
gets are indeed directly regulated by this 
factor in a PI3K-responsive manner and 
whether the poor prognosis associated 
with the cluster of tumors with relatively 
low expression of PI3K-repressed genes 
actually reflects diminished levels of 
apoptosis or altered proliferative proper-ier Inc.ties of these tumors. As a final test of the 
power of this approach, it will be most 
exciting to test the therapeutic value 
of chemically inhibiting PI3K signaling 
in these tumors to assess whether the 
apoptotic arm emanating from the E2F1-
associated fulcrum can be restored, 
thereby improving the prognosis (Figure 
1). The results presented here reinforce 
an independent study that showed the 
importance of PI3K activation in breast 
cancer and that pinpointed the activa-
tion of this pathway as a biomarker for 
responsiveness to antitumor treatments 
in a cohort of breast cancer patients 
(Berns et al., 2007).
It is quite curious that, to date, few 
human tumors have been associated 
with amplification of the E2F1 gene, 
while many tumors exhibit mutations 
or loss of the RB gene. This interest-
ing study suggests that it may be worth 
taking a closer look at the occurrence 
of synergistic collaborations between 
amplified E2F1 and PI3K pathway 
defects in human cancer.
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